|
1
|
El-Salhy M, Danielsson A, Stenling R and
Grimelius L: Colonic endocrine cells in inflammatory bowel disease.
J Intern Med. 242:413–419. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Chromogranin a cell density as a diagnostic marker for
lymphocytic colitis. Dig Dis Sci. 57:3154–3159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: High densities of serotonin and peptide YY cells in the
colon of patients with lymphocytic colitis. World J Gastroenterol.
18:6070–6075. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Salhy M, Lomholt-Beck B and Gundersen
TD: High chromogranin A cell density in the colon of patients with
lymphocytic colitis. Mol Med Rep. 4:603–605. 2011.PubMed/NCBI
|
|
5
|
Moran GW, Pennock J and McLaughlin JT:
Enteroendocrine cells in terminal ileal Crohn's disease. J Crohns
Colitis. 6:871–880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moran GW, Leslie FC and McLaughlin JT:
Crohn's disease affecting the small bowel is associated with
reduced appetite and elevated levels of circulating gut peptides.
Clin Nutr. 32:404–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Besterman HS, Mallinson CN, Modigliani R,
Christofides ND, Pera A, Ponti V, Sarson DL and Bloom SR: Gut
hormones in inflammatory bowel disease. Scand J Gastroenterol.
18:845–852. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Salhy M, Mazzawi T, Gundersen D,
Hatlebakk JG and Hausken T: The role of peptide YY in
gastrointestinal diseases and disorders (Review). Int J Mol Med.
31:275–282. 2013.PubMed/NCBI
|
|
9
|
Hirotani Y, Mikajiri K, Ikeda K, Myotoku M
and Kurokawa N: Changes of the peptide YY levels in the intestinal
tissue of rats with experimental colitis following oral
administration of mesalazine and prednisolone. Yakugaku Zasshi.
128:1347–1353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vona-Davis LC and McFadden DW: NPY family
of hormones: Clinical relevance and potential use in
gastrointestinal disease. Curr Top Med Chem. 7:1710–1720. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Salhy M, Suhr O and Danielsson A:
Peptide YY in gastrointestinal disorders. Peptides. 23:397–402.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tari A, Teshima H, Sumii K, Haruma K,
Ohgoshi H, Yoshihara M, Kajiyama G and Miyachi Y: Peptide YY
abnormalities in patients with ulcerative colitis. Jpn J Med.
27:49–55. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sciola V, Massironi S, Conte D, Caprioli
F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT and Piodi L:
Plasma chromogranin a in patients with inflammatory bowel disease.
Inflamm Bowel Dis. 15:867–871. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bishop AE, Pietroletti R, Taat CW,
Brummelkamp WH and Polak JM: Increased populations of endocrine
cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol.
410:391–396. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manocha M and Khan WI: Serotonin and GI
disorders: An update on clinical and experimental studies. Clin
Transl Gastroenterol. 3:e132012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stoyanova II and Gulubova MV: Mast cells
and inflammatory mediators in chronic ulcerative colitis. Acta
Histochem. 104:185–192. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamoto H, Morise K, Kusugami K, Furusawa
A, Konagaya T, Nishio Y, Kaneko H, Uchida K, Nagai H, Mitsuma T and
Nagura H: Abnormal neuropeptide concentration in rectal mucosa of
patients with inflammatory bowel disease. J Gastroenterol.
31:525–532. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Payer J, Huorka M, Duris I, Mikulecky M,
Kratochvílová H, Ondrejka P and Lukác L: Plasma somatostatin levels
in ulcerative colitis. Hepatogastroenterology. 41:552–553.
1994.PubMed/NCBI
|
|
19
|
Watanabe T, Kubota Y, Sawada T and Muto T:
Distribution and quantification of somatostatin in inflammatory
disease. Dis Colon Rectum. 35:488–494. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koch TR, Carney JA, Morris VA and Go VL:
Somatostatin in the idiopathic inflammatory bowel diseases. Dis
Colon Rectum. 31:198–203. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khan WI and Ghia JE: Gut hormones:
Emerging role in immune activation and inflammation. Clin Exp
Immunol. 161:19–27. 2010.PubMed/NCBI
|
|
22
|
Margolis KG and Gershon MD: Neuropeptides
and inflammatory bowel disease. Curr Opin Gastroenterol.
25:503–511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bampton PA and Dinning PG: High resolution
colonic manometry-what have we learnt?-A review of the literature
2012. Curr Gastroenterol Rep. 15:3282013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ameri P and Ferone D: Diffuse endocrine
system, neuroendocrine tumors and immunity: What's new?
Neuroendocrinology. 95:267–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Farzi A, Reichmann F and Holzer P: The
homeostatic role of neuropeptide Y in immune function and its
impact on mood and behaviour. Acta Physiol (Oxf). 213:603–627.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
El-Salhy M and Hausken T: The role of the
neuropeptide Y (NPY) family in he pathophysiology of inflammatory
bowel disease (IBD). Neuropeptides. 55:137–144. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wheway J, Herzog H and Mackay F: NPY and
receptors in immune and inflammatory diseases. Curr Top Med Chem.
7:1743–1752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wheway J, Herzog H and Mackay F: The Y1
receptor for NPY: A key modulator of the adaptive immune system.
Peptides. 28:453–458. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wheway J, Mackay CR, Newton RA, Sainsbury
A, Boey D, Herzog H and Mackay F: A fundamental bimodal role for
neuropeptide Y1 receptor in the immune system. J Exp Med.
202:1527–1538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Clinical presentation, diagnosis, pathogenesis and
treatment options for lymphocytic colitis (Review). Int J Mol Med.
32:263–270. 2013.PubMed/NCBI
|
|
31
|
El-Salhy M, Hatlebakk JG and Gilja OH: The
abnormalities in endocrine and immune cells are correlated in
dextran-sulfate-sodium-induced colitis. Mol Med Rep. in press.
2016.
|
|
32
|
El-Salhy M, Umezawa K, Gilja OH, Hatlebakk
JG, Gundersen D and Hausken T: Amelioration of Severe TNBS Induced
Colitis by Novel AP-1 and NF-κB Inhibitors in Rats. Sci World J.
2014:1–8. 2014. View Article : Google Scholar
|
|
33
|
Vermeulen W, De Man JG, Nullens S,
Pelckmans PA, De Winter BY and Moreels TG: The use of colonoscopy
to follow the inflammatory time course of TNBS colitis in rats.
Acta Gastroenterol Belg. 74:304–311. 2011.PubMed/NCBI
|
|
34
|
Saleh M and Elson CO: Experimental
inflammatory bowel disease: Insights into the host-microbiota
dialog. Immunity. 34:293–302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carter MJ, Lobo AJ and Travis SP: IBD
Section, British Society of Gastroenterology: Guidelines for the
management of inflammatory bowel disease in adults. Gut. 53:(Suppl
5). V1–V16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sands BE: New therapies for the treatment
of inflammatory bowel disease. Surg Clin North Am. 86:1045–1064.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lopez A, Billioud V, Peyrin-Biroulet C and
Peyrin-Biroulet L: Adherence to anti-TNF therapy in inflammatory
bowel diseases: A systematic review. Inflamm Bowel Dis.
19:1528–1533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Danese S, Semeraro S, Armuzzi A, Papa A
and Gasbarrini A: Biological therapies for inflammatory bowel
disease: Research drives clinics. Mini Rev Med Chem. 6:771–784.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elson CO, Sartor RB, Tennyson GS and
Riddell RH: Experimental models of inflammatory bowel disease.
Gastroenterology. 109:1344–1367. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dieleman LA, Palmen MJ, Akol H, Bloemena
E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental
colitis induced by dextran sulphate sodium (DSS) is characterized
by Th1 and Th2 cytokines. Clin Exp Immunol. 114:385–391. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Low D, Nguyen DD and Mizoguchi E: Animal
models of ulcerative colitis and their application in drug
research. Drug Des Devel Ther. 7:1341–1357. 2013.PubMed/NCBI
|
|
42
|
Öhman L, Törnblom H and Simrén M:
Crosstalk at the mucosal border: Importance of the gut
microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 12:36–49.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buffa R, Mare P, Gini A and Salvadore M:
Chromogranins A and B and secretogranin II in hormonally identified
endocrine cells of the gut and the pancreas. Basic Appl Histochem.
32:471–484. 1988.PubMed/NCBI
|
|
44
|
Eiden LE: Is chromogranin a prohormone?
Nature. 325:3011987. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Buffa R, Capella C, Fontana P, Usellini L
and Solcia E: Types of endocrine cells in the human colon and
rectum. Cell Tissue Res. 192:227–240. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Curry WJ, Johnston CF, Hutton JC, Arden
SD, Rutherford NG, Shaw C and Buchanan KD: The tissue distribution
of rat chromogranin A-derived peptides: Evidence for differential
tissue processing from sequence specific antisera. Histochemistry.
96:531–538. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Portela-Gomes GM and Stridsberg M:
Selective processing of chromogranin A in the different islet cells
in human pancreas. J Histochem Cytochem. 49:483–490. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Portela-Gomes GM and Stridsberg M:
Chromogranin A in the human gastrointestinal tract: An
immunocytochemical study with region-specific antibodies. J
Histochem Cytochem. 50:1487–1492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Taupenot L, Harper KL and O'Connor DT: The
chromogranin-secretogranin family. N Engl J Med. 348:1134–1149.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wiedenmann B and Huttner WB: Synaptophysin
and chromogranins/secretogranins-widespread constituents of
distinct types of neuroendocrine vesicles and new tools in tumor
diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 58:95–121.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Spiller R: Serotonin and GI clinical
disorders. Neuropharmacology. 55:1072–1080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Egger M, Beer AG, Theurl M, Schgoer W,
Hotter B, Tatarczyk T, Vasiljevic D, Frauscher S, Marksteiner J,
Patsch JR, et al: Monocyte migration: A novel effect and signaling
pathways of catestatin. Eur J Pharmacol. 598:104–111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Feistritzer C, Mosheimer BA, Colleselli D,
Wiedermann CJ and Kähler CM: Effects of the neuropeptide
secretoneurin on natural killer cell migration and cytokine
release. Regul Pept. 126:195–201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ferrero E, Magni E, Curnis F, Villa A,
Ferrero ME and Corti A: Regulation of endothelial cell shape and
barrier function by chromogranin A. Ann N Y Acad Sci. 971:355–358.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bertrand PP and Bertrand RL: Serotonin
release and uptake in the gastrointestinal tract. Auton Neurosci.
153:47–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qian BF, El-Salhy M, Melgar S, Hammarström
ML and Danielsson A: Neuroendocrine changes in colon of mice with a
disrupted IL-2 gene. Clin Exp Immunol. 120:424–433. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Oshima S, Fujimura M and Fukimiya M:
Changes in number of serotonin-containing cells and serotonin
levels in the intestinal mucosa of rats with colitis induced by
dextran sodium sulfate. Histochem Cell Biol. 112:257–263. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cloëz-Tayarani I and Changeux JP: Nicotine
and serotonin in immune regulation and inflammatory processes: A
perspective. J Leukoc Biol. 81:599–606. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang H, Steeds J, Motomura Y, Deng Y,
Verma-Gandhu M, El-Sharkawy RT, McLaughlin JT, Grencis RK and Khan
W: CD4+ T cell-mediated immunological control of enterochromaffin
cell hyperplasia and 5-hydroxytryptamine production in enteric
infection. Gut. 56:949–957. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Stefulj J, Cicin-Sain L, Schauenstein K
and Jernej B: Serotonin and immune response: Effect of the amine on
in vitro proliferation of rat lymphocytes. Neuroimmunomodulation.
9:103–108. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Betten A, Dahlgren C, Hermodsson S and
Hellstrand K: Serotonin protects NK cells against oxidatively
induced functional inhibition and apoptosis. J Leukoc Biol.
70:65–72. 2001.PubMed/NCBI
|
|
62
|
Laberge S, Cruikshank WW, Beer DJ and
Center DM: Secretion of IL-16 (lymphocyte chemoattractant factor)
from serotonin-stimulated CD8+ T cells in vitro. J Immunol.
156:310–315. 1996.PubMed/NCBI
|
|
63
|
Soga F, Katoh N, Inoue T and Kishimoto S:
Serotonin activates human monocytes and prevents apoptosis. J
Invest Dermatol. 127:1947–1955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
El-Salhy M, Seim I, Chopin L, Gundersen D,
Hatlebakk JG and Hausken T: Irritable bowel syndrome: The role of
gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800.
2012.PubMed/NCBI
|
|
65
|
El-Salhy M: Irritable bowel syndrome:
Diagnosis, pathogenesis and treatment options. World J
Gastroenterol. 18:5151–5163. 2012.PubMed/NCBI
|
|
66
|
Spångéus A, Forsgren S and el-Salhy M:
Does diabetic state affect co-localization of peptide YY and
enteroglucagon in colonic endocrine cells? Histol Histopathol.
15:37–41. 2000.PubMed/NCBI
|
|
67
|
Pyarokhil AH, Ishihara M, Sasaki M and
Kitamura N: The developmental plasticity of colocalization pattern
of peptide YY and glucagon-like peptide-1 in the endocrine cells of
bovine rectum. Biomed Res. 33:35–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
De la Fuente M, Bernaez I, Del Rio M and
Hernanz A: Stimulation of murine peritoneal macrophage functions by
neuropeptide Y and peptide YY. Involvement of protein kinase C.
Immunology. 80:259–265. 1993.PubMed/NCBI
|
|
69
|
Macia L, Yulyaningsih E, Pangon L, Nguyen
AD, Lin S, Shi YC, Zhang L, Bijker M, Grey S, Mackay F, et al:
Neuropeptide Y1 receptor in immune cells regulates inflammation and
insulin resistance associated with diet-induced obesity. Diabetes.
61:3228–3238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
El-Salhy M, Gundersen D, Gilja OH,
Hatlebakk JG and Hausken T: Is irritable bowel syndrome an organic
disorder? World J Gastroenterol. 20:384–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Payan DG, Hess CA and Goetzl EJ:
Inhibition by somatostatin of the proliferation of T-lymphocytes
and Molt-4 lymphoblasts. Cell Immunol. 84:433–438. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Adeyemi EO, Savage AP, Bloom SR and
Hodgson HJ: Somatostatin inhibits neutrophil elastase release in
vitro. Peptides. 11:869–871. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Stanisz AM, Befus D and Bienenstock J:
Differential effects of vasoactive intestinal peptide, substance P,
and somatostatin on immunoglobulin synthesis and proliferations by
lymphocytes from Peyer's patches, mesenteric lymph nodes, and
spleen. J Immunol. 136:152–156. 1986.PubMed/NCBI
|
|
74
|
Scicchitano R, Dazin P, Bienenstock J,
Payan DG and Stanisz AM: Distribution of somatostatin receptors on
murine spleen and Peyer's patch T and B lymphocytes. Brain Behav
Immun. 1:173–184. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Scicchitano R, Stanisz AM, Payan DG,
Kiyono H, McGhee JR and Bienenstock J: Expression of substance P
and somatostatin receptors on a T helper cell line. Adv Exp Med
Biol 216A. 185–190. 1987. View Article : Google Scholar
|
